[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Wall St Engine [@wallstengine](/creator/twitter/wallstengine) on x 72.2K followers Created: 2025-07-11 09:50:57 UTC Citi Opens 90-Day Upside Catalyst Watch on $MDT, Reiterates Buy Rating, PT $XX Analyst comments: "CMS has posted its draft decision memo for covering renal denervation (RDN), with proposed coverage in line with our expectations. CMS is proposing to cover RDN in patients with uncontrolled hypertension defined as >140/90 mm Hg despite 'active management by a clinician with primary responsibility for blood pressure management' and on stable doses of maximally tolerated guideline-directed medical therapy for at least three months. Additionally, the primary providers must manage the patient for at least six months prior to performing RDN and must complete five proctored procedures for each device used. The patient coverage criteria align with Symplicity Spyral’s FDA label and the patients studied in the SPYRAL HTN ON-MED study. We believe today’s memo is largely in line with investor expectations, and we expect the stock to react favorably. The final memo is expected on October 8, 2025. Entering into the FY1Q26 earnings cycle, we are opening a Positive Short-term View as Medtronic anticipates a handful of product approvals in the coming months, including: X. A draft National Coverage Determination from CMS for its Symplicity Spyral renal denervation system to address treatment-resistant hypertension on or before July 13, and a final NCD on or before October XX. X. For the Hugo surgical robot, Medtronic filed with the FDA for the urology indication in late April 2025, which we expect to be approved in the coming months. X. For the Minimed 780G, Type X Diabetes and rapid-acting insulin label expansions were also submitted in FY4Q25, plus pump combination with Abbott’s Libre CGM, which we expect in the coming months. We reiterate our Buy rating on Medtronic." Analyst: Joanna Wuensch XXXXX engagements  **Related Topics** [$mdt](/topic/$mdt) [medtronic](/topic/medtronic) [coins solana ecosystem](/topic/coins-solana-ecosystem) [coins base ecosystem](/topic/coins-base-ecosystem) [stocks healthcare](/topic/stocks-healthcare) [$99](/topic/$99) [Post Link](https://x.com/wallstengine/status/1943608943206613412)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wall St Engine @wallstengine on x 72.2K followers
Created: 2025-07-11 09:50:57 UTC
Citi Opens 90-Day Upside Catalyst Watch on $MDT, Reiterates Buy Rating, PT $XX
Analyst comments: "CMS has posted its draft decision memo for covering renal denervation (RDN), with proposed coverage in line with our expectations. CMS is proposing to cover RDN in patients with uncontrolled hypertension defined as >140/90 mm Hg despite 'active management by a clinician with primary responsibility for blood pressure management' and on stable doses of maximally tolerated guideline-directed medical therapy for at least three months. Additionally, the primary providers must manage the patient for at least six months prior to performing RDN and must complete five proctored procedures for each device used.
The patient coverage criteria align with Symplicity Spyral’s FDA label and the patients studied in the SPYRAL HTN ON-MED study. We believe today’s memo is largely in line with investor expectations, and we expect the stock to react favorably. The final memo is expected on October 8, 2025. Entering into the FY1Q26 earnings cycle, we are opening a Positive Short-term View as Medtronic anticipates a handful of product approvals in the coming months, including:
X. A draft National Coverage Determination from CMS for its Symplicity Spyral renal denervation system to address treatment-resistant hypertension on or before July 13, and a final NCD on or before October XX.
X. For the Hugo surgical robot, Medtronic filed with the FDA for the urology indication in late April 2025, which we expect to be approved in the coming months.
X. For the Minimed 780G, Type X Diabetes and rapid-acting insulin label expansions were also submitted in FY4Q25, plus pump combination with Abbott’s Libre CGM, which we expect in the coming months.
We reiterate our Buy rating on Medtronic."
Analyst: Joanna Wuensch
XXXXX engagements
Related Topics $mdt medtronic coins solana ecosystem coins base ecosystem stocks healthcare $99